Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
 |
Results for 'Boehringer Ingelheim: PharmaVitae Profile' |
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
|
Boehringer Ingelheim GmbH: PharmaVitae Profile |
March 2009 | £3010 | 100 % |
|
Boehringer Ingelheim IMS Company Profile |
November 2008 | £510 | 79 % |
|
Boehringer Ingelheim GmbH Strategic Analysis Profile |
November 1999 | £500 | 78 % |
|
Boehringer Ingelheim GmbH - SWOT Analysis |
June 2008 | £66 | 35 % |
|
Boehringer Ingelheim GmbH Deals Partneringdesk briefing |
July 2005 | £215 | 23.45 % |
|
Boehringer Ingelheim Gmbh Pharmavitae Profile |
December 2007 | £3010 | 21.35 % |
|
Partnering Agreements with Boehringer Ingelheim 2010 |
January 2010 | £295 | 17.15 % |
|
Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape |
August 2008 | £3800 | 13.3 % |
|
Eye Care in Denmark |
May 2006 | £450 | 10.85 % |
|
Eye Care in Mexico |
February 2008 | £450 | 10.5 % |
|
Analgesics in Mexico |
February 2008 | £450 | 10.5 % |
|
Abbott Laboratories Pharmavitae Profile |
December 2007 | £3010 | 10.5 % |
|
Wound Treatments in Mexico |
September 2006 | £450 | 10.5 % |
|
Wound Treatments in Denmark |
May 2006 | £450 | 10.5 % |
|
Vitamins and Dietary Supplements in Mexico |
September 2006 | £450 | 9.8 % |
|
Vitamins and Dietary Supplements in Denmark |
May 2006 | £450 | 9.8 % |
|
Cardiovascular Pharmaceutical Market Trends, 2007 to 2010 Key market forecasts and growth opportunities |
August 2007 | £895 | 9.45 % |
|
Mergers and Aquisitions in the Pharmaceuticals Sector, 2009 Critical success factors for competing in a consolidating market |
April 2009 | £995 | 9.45 % |
|
Mergers and Acquisitions in the Pharmaceuticals Sector, 2009 Critical success factors for competing in a consolidating market |
April 2009 | £1955 | 9.45 % |
|
Diabetes Market Forecast to 2015 |
January 2010 | £6360 | 9 % |
|
Medicated Skin Care in Venezuela |
February 2008 | £450 | 8.75 % |
|
Vitamins And Dietary Supplements in Germany |
August 2007 | £450 | 8.75 % |
|
Merck KGaA - OTC Healthcare - World |
January 2008 | £195 | 8.4 % |
|
Argentina Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012 |
November 2008 | £1910 | 8.4 % |
|
Mexico Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012 |
November 2008 | £1910 | 8.4 % |
|
Bigpharma Dealmaking Handbook Companies & Contacts |
September 2008 | £1195 | 8.05 % |
|
Republic of Korea Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012 |
December 2008 | £1910 | 8.05 % |
|
ResMed Inc. Strategic Analysis Profile |
November 1999 | £500 | 7.7 % |
|
Bigpharma Dealmaking and Agreements Handbook 2007 Companies, Contacts & Partnering Agreements |
September 2007 | £1195 | 7.7 % |
|
Brazil Drug Delivery Devices Investment Opportunities Analysis and Forecasts to 2015 |
March 2009 | £1590 | 7.35 % |
|
Atrial Fibrillation Drug Pipeline Analysis and Market Forecasts to 2016 |
February 2010 | £1275 | 7 % |
|
Partnering with Biopharma The definitive guide to bigpharma partnering interests, contacts & agreements |
July 2008 | £1495 | 7 % |
|
Digestive Remedies in China |
September 2007 | £450 | 6.65 % |
|
Australia Drug Delivery Devices Investment Opportunities Analysis and Forecasts to 2015 |
March 2009 | £1590 | 6.65 % |
|
United States Pharmaceuticals and Healthcare Report Q3 2006 |
July 2006 | £395 | 6.5 % |
|
Digestive Remedies in Brazil |
August 2007 | £450 | 6.3 % |
|
Digestive Remedies in Argentina |
August 2007 | £450 | 6.3 % |
|
Analyzing the Nutraceuticals Market in the UK |
January 2009 | £575 | 5.95 % |
|
Mexico Pharmaceuticals and Healthcare Report Q3 2008 |
July 2008 | £425 | 5.95 % |
|
The Global Antivirals Market R&D Pipelines, Market Analysis and Competitive Landscape |
May 2007 | £1590 | 5.6 % |
|
Commercial Insight: HIV - The battle for market share is getting fiercer |
August 2008 | £7600 | 5.6 % |
|
Global Drug Delivery Devices Investment Opportunities Analysis and Forecasts to 2015 |
March 2009 | £2545 | 4.9 % |
|
United Sates Drug Delivery Devices Investment Opportunities Analysis and Forecasts to 2015 |
March 2009 | £1590 | 4.55 % |
|
Commercial Insight: Asthma & COPD |
June 2009 | £15200 | 4.2 % |
|
Licensing Strategies - Examining Todays Pharmaceutical Licensing Trends |
November 2007 | £7600 | 4.2 % |
|
Lymphoma Drug Development Strategies at Work |
June 2009 | £1700 | 3.85 % |
|
China Pharma Outsourcing Annual Review 2009 |
November 2009 | £880 | 3.85 % |
|
The Japanese Pharmaceutical Market Outlook to 2014 Policy environment, market structure, competitive landscape, growth opportunities |
January 2010 | £3835 | 3.5 % |
|
Quality for Biologics Critical quality attributes, process and change control, product variation, characterisation, and regulatory concerns |
December 2008 | £1495 | 3.15 % |
|
Competitive Outlook of Cancer Drug Development The Missing Handbook to New Product Planning and Portfolio Planning |
August 2009 | £2140 | 3.15 % |
|
Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements |
April 2008 | £6000 | 2.8 % |
|
Leukemia A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking |
April 2009 | £1700 | 2.8 % |
|
Pipeline Insight: Molecular Targeted Cancer Therapies More pipeline activity, less product differentiation |
November 2008 | £8000 | 2.8 % |
|
ASCO 2009: Significant Developments in Context |
July 2009 | £595 | 2.45 % |
|
CNS Drug Discoveries What the Future Holds |
November 2006 | £1995 | 2.1 % |
|
China Pharma Outsourcing Market By 2015 |
January 2009 | £1110 | 2.1 % |
|
Monoclonal Antibody Therapeutics 2009-2024 |
August 2009 | £1499 | 1.75 % |
|
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012 |
April 2007 | £1499 | 1.75 % |
